| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Fmoc-N-Me-D-Leu-OH is classified as a protected N-methylated D-amino acid and does not have a specific biological receptor target. Its primary application is as a building block for introducing N-methyl-D-leucine residues into peptides during Fmoc SPPS. The D-configuration provides proteolytic stability, while N-methylation enhances permeability and reduces hydrogen bond donation.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
In vitro activity for Fmoc-N-Me-D-Leu-OH is primarily as a peptide synthesis reagent. Amino acid derivatives have been commercially used as ergogenic supplements. Fmoc-N-Me-D-Leu-OH itself is not directly biologically active. Its utility is in preparing N-methyl-D-leucine-containing peptides for subsequent biological evaluation. |
| ln Vivo |
In vivo activity data for Fmoc-N-Me-D-Leu-OH as a standalone compound is not applicable. It is a protected N-methylated D-amino acid building block used in research. Peptides synthesized using this building block may be evaluated in animal models. N-methylation and D-configuration can improve peptide stability, permeability, and reduce enzymatic degradation.
|
| Enzyme Assay |
In vitro SPPS protocols for Fmoc-N-Me-D-Leu-OH involve standard Fmoc chemistry. The compound is activated with coupling reagents such as HATU or HBTU and DIPEA in DMF, then coupled to resin-bound peptides. Fmoc deprotection uses 20% piperidine in DMF. The N-methyl group can slow coupling kinetics. Purity is ≥97% by HPLC. Melting point is 108-116°C.
|
| Cell Assay |
Cell-based protocols are not directly applicable to Fmoc-N-Me-D-Leu-OH as it is a protected amino acid derivative. N-Methyl-D-leucine-containing peptides synthesized using this reagent can be tested in cell culture after deprotection. Peptides are dissolved in DMSO or appropriate buffers and added to cells at concentrations of 0.1-100 µM for 24-72 hours.
|
| Animal Protocol |
Animal studies with Fmoc-N-Me-D-Leu-OH are not conducted directly. Peptides containing N-methyl-D-leucine residues synthesized using this building block may be evaluated in vivo. Protocols involve administration of the peptide via appropriate routes in animal models. Pharmacokinetic sampling, efficacy assessment, and toxicological evaluation follow standard preclinical study designs.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Fmoc-N-Me-D-Leu-OH as a standalone compound is not applicable. The compound has a molecular weight of 367.44 g/mol, formula C22H25NO4, and CAS number 103478-63-3. It appears as a colorless to white powder. Storage is recommended in a cool, dry place. The Fmoc group is removed under basic conditions during peptide synthesis.
|
| Toxicity/Toxicokinetics |
Limited toxicological data is available for Fmoc-N-Me-D-Leu-OH. The compound is for research use only. Standard safety precautions should be observed. No specific toxicity studies have been reported. It is not intended for human therapeutic use.
|
| References |
[1]. Luckose F, et al. Effects of amino acid derivatives on physical, mental, and physiological activities. Crit Rev Food Sci Nutr. 2015;55(13):1793-1144.
|
| Additional Infomation |
Fmoc-N-Me-D-Leu-OH (CAS#: 103478-63-3) is also known as N-α-Fmoc-N-α-methyl-D-leucine and (R)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-4-methylpentanoic acid. It is a protected amino acid used in peptide synthesis. It has no approved therapeutic indications.
|
| Molecular Formula |
C22H25NO4
|
|---|---|
| Molecular Weight |
367.4382
|
| Exact Mass |
367.178
|
| CAS # |
103478-63-3
|
| PubChem CID |
7019520
|
| Appearance |
White to off-white powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
537.3±29.0 °C at 760 mmHg
|
| Flash Point |
278.7±24.3 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.581
|
| LogP |
5.44
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
27
|
| Complexity |
512
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC(C)C[C@H](C(=O)O)N(C)C(=O)OCC1C2=CC=CC=C2C3=CC=CC=C13
|
| InChi Key |
BUJQSIPFDWLNDC-HXUWFJFHSA-N
|
| InChi Code |
InChI=1S/C22H25NO4/c1-14(2)12-20(21(24)25)23(3)22(26)27-13-19-17-10-6-4-8-15(17)16-9-5-7-11-18(16)19/h4-11,14,19-20H,12-13H2,1-3H3,(H,24,25)/t20-/m1/s1
|
| Chemical Name |
(2R)-2-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]-4-methylpentanoic acid
|
| Synonyms |
N-(((9H-Fluoren-9-yl)methoxy)carbonyl)-N-methyl-D-leucine; Fmoc-N-Me-D-Leu-OH
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7215 mL | 13.6077 mL | 27.2153 mL | |
| 5 mM | 0.5443 mL | 2.7215 mL | 5.4431 mL | |
| 10 mM | 0.2722 mL | 1.3608 mL | 2.7215 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
